Shares of Alkem Laboratories Ltd were trading in the green and 1% higher on 5 February after the company announced launching Kojiglo serum in India, which is used for managing facial hyperpigmentation and is suitable for all skin types.
The company is the first in India to introduce a liposomal serum using Duo-Lipo technology.
This groundbreaking formulation features a unique blend of liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide. The company stated that it is the first in India to incorporate Duo-Lipo technology.
The advanced serum utilizes liposomal encapsulation to enhance skin penetration and deliver targeted benefits, ensuring maximum efficacy, the company added.
The board will meet on 7 February 2025 to review and approve the company’s standalone and consolidated unaudited financial results for the quarter and nine months ending 31 December 2024.
In addition, the board will review and approve the interim dividend for the 2024–2025 fiscal year.
Depending on the declaration, the business has chosen 14 February as the record date for the interim dividend payment for the fiscal year 2024–2025.
At 11:51 am, the shares of Alkem Laboratories were trading 0.49% higher at Rs 5,131.05 on NSE.
The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!